Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorders of Calcium and Bone Metabolism Clear all
Completed Phase 4 Interventional Results available

Vitamin D and Coronary Calcification Study

NCT00752102
View directory record Official record
Conditions
Chronic Kidney Disease, Vitamin D Deficiency, Coronary Calcification, Disorders of Calcium and Bone Metabolism
Interventions
Calcitriol (Rocaltrol®), Paricalcitol
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
25 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 8, 2026, 10:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

NCT00415584
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Hypercalcemia
Interventions
Cinacalcet HCl
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)

NCT02463409
View directory record Official record
Conditions
Pseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
Interventions
Theophylline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

NCT00525798
View directory record Official record
Conditions
Osteoporosis
Interventions
SMC021 Oral calcitonin, SMC021 Placebo
Drug
Lead sponsor
Nordic Bioscience A/S
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
4,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Gainesville, Georgia • Detroit, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

NCT00417612
View directory record Official record
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 8, 2026, 10:30 AM EDT
Withdrawn Not applicable Interventional

Association of Bone Quality and Quantity With Vascular Calcification

NCT00892853
View directory record Official record
Conditions
Vascular Calcification, Atherosclerosis, Bone Density
Interventions
CT of the bones
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Oct 8, 2026, 10:30 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

NCT05998863
View directory record Official record
Conditions
Osteoporosis, Hypomagnesemia
Interventions
EffCaMgCit, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.

NCT00468689
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689 oral tablets (100 and 400 ng), Ketoconazole (NIZORAL) oral tablets (200 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2008 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women

NCT00043719
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Nitroglycerin ointment, Calcium supplement with vitamin D
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
40 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Vitamin D Supplementation in Breastfeeding Women

NCT01240265
View directory record Official record
Conditions
Vitamin D Deficiency, Rickets, Infant Nutrition Disorders
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Month to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 8, 2026, 10:30 AM EDT
Completed No phase listed Observational

Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome

NCT00001973
View directory record Official record
Conditions
Polyostotic Fibrous Dysplasia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism

NCT00671944
View directory record Official record
Conditions
Osteoporosis
Interventions
Low protein diet
Other
Lead sponsor
Yale University
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 8, 2026, 10:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Age Related Changes in Calciotropic Hormones and Their Impact on Male Osteoporosis

NCT00588874
View directory record Official record
Conditions
Low Bone Density
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
50 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Encouraging Calcium Absorption and Bone Formation During Early Puberty

NCT00022867
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Nondigestible oligosaccharide (NDO)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 8, 2026, 10:30 AM EDT
Active, not recruiting Not applicable Interventional

Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

NCT00209235
View directory record Official record
Conditions
Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
Interventions
Neurocognitive and psychosocial testing
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
2 Months to 89 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

NCT00744042
View directory record Official record
Conditions
Hypophosphatasia (HPP)
Interventions
asfotase alfa
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 36 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Springfield, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 8, 2026, 10:30 AM EDT
Terminated Phase 4 Interventional Results available

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

NCT01725113
View directory record Official record
Conditions
Kidney Failure, Secondary Hyperparathyroidism, Hyperphosphatemia, Hypercalcemia
Interventions
Calcitriol, Paricalcitol
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 8, 2026, 10:30 AM EDT
Completed No phase listed Observational

Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease

NCT03626246
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Secondary Hyperparathyroidism
Interventions
Kidney disease
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Etelcalcetide on CKD-MBD

NCT03960437
View directory record Official record
Conditions
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
Interventions
Etelcalcetide
Drug
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 1 Interventional

The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

NCT00316472
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Niacinamide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2009 · Synced Oct 8, 2026, 10:30 AM EDT
Completed No phase listed Observational Results available

A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

NCT01419028
View directory record Official record
Conditions
Hypophosphatasia (HPP)
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 8, 2026, 10:30 AM EDT
Active, not recruiting Phase 2 Interventional

Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old

NCT04551170
View directory record Official record
Conditions
Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism Type 1a
Interventions
Theophylline, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
2 Years to 12 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 4 Interventional Results available

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

NCT00668200
View directory record Official record
Conditions
Paget's Disease of the Bone, Hypocalcemia
Interventions
Reclast (ZOL446, zoledronic acid), Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Tucson, Arizona • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 8, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

NCT02163577
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
5 Years to 12 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 8, 2026, 10:30 AM EDT